Top Lobby Spenders in Healthcare

Published on: 

The American Medical Association invested heavily in DC influence in the first two quarters of 2015. PhRMA wasn't far behind. Casey McDonald reports.

The American Medical Association invested heavily in DC influence in the first two quarters of 2015. The AMA dropped $12.4m in the second quarter of 2015, more than it has spent in any single quarter since 2008, according to a MapLight report. The group spent $19.1m in the first half of the year, more than its total in prior years ($18.8m in 2014).

Also on the MapLight top 10 list for 2Q15 lobby spending is Pharmaceutical Research & Manufacturers of America (PhRMA) which spent $4.8m from May through June. PhRMA’s $10.2m spend so far in 2015 tracks slightly above in 1H14 and 1H13 putting it on track for an up year.

AMA and PhRMA are numbers 5 and 6 on MapLight’s all time spenders, having spent $154.8m and $149.8m, respectively, since 2008.

It doesn’t take too many clicks to find the pharma industry’s top spender. Pfizer totals out at $92.8m since 2008 (33rd on the list), with what looks to be a fairly standard year so far, $4.9m in the first two quarters.

Amgen and Lilly take spots at 43rd and 44th on the list. Amgen has spent $74.8m since 2008 and $4.9m so far this year. For Lilly, $73.1m since 2008 and $3.9m in 1H15.

Some other notables:

49 - American Health Insurance Plans

52 - CVS Caremark

57 - Biotechnology Industry Organization (BIO)

59 - Blue Cross Blue Shield Association

63 - Monsanto

66 - Merck

69 - Novartis

74 - Dupont

76 - J&J

81 - Bayer

83 - Sanofi


85 - GlaxoSmithKline

110 - Medtronic

122 - Proctor & Gamble

125 - Genentech

133 - Fresenius Medical Care

138 - Abbott Labs

139 - AstraZeneca

140 - American Cancer Society Action Network

162 - Teva

169 - Aetna

170 - UnitedHealth Group

172 - Bristol-Myers Squibb

178 - Baxter International

180 - Emergent BioSolutions

Search for yourself to see some of the esteemed organizations and companies who made the list.

Accoring to the MapList methodology statement, the analysis of 2Q figures are gleaned from of federal lobbying disclosure filings from the Clerk of the U.S. House of Representatives between April 1, 2015, and June 30, 2015.